间充质干细胞分泌组在体外提高腱细胞活力并在慢性巨大肩袖撕裂大鼠模型中结合组织工程策略改善腱骨愈合
本研究为对照实验室研究,将人肌腱细胞经人间充质干细胞分泌组(条件培养基)预处理后接种于静电纺丝角蛋白支架,植入慢性巨大肩袖撕裂大鼠模型。术后16周组织学显示STC_hMSC_CM组腱成熟评分显著高于MRCT组,生物力学显示总断裂伸长率增加、刚度降低。结论认为该组织工程策略可改善慢性巨大肩袖撕裂的腱骨愈合。
要点
- 人间充质干细胞分泌组在体外提高人肌腱细胞活力和密度。
- STC_hMSC_CM组腱成熟评分15.6±1.08,显著高于MRCT组11.0±1.38(P<.05)。
- STC_hMSC_CM组总断裂伸长率11.99±3.30 mm,MRCT组5.86±3.16 mm(P<.05),刚度低于MRCT组(P<.01)。
核心结论
- 人间充质干细胞条件培养基在体外提高人肌腱细胞活力和密度。
- 将经预处理的人肌腱细胞整合入静电纺丝角蛋白支架的组织工程策略后,STC_hMSC_CM组组织学和生物力学性能较MRCT组改善。
- 作者认为该工作支持进一步研究间充质干细胞分泌组预处理肌腱细胞,并推动该组织工程策略作为改善慢性巨大肩袖撕裂治疗结果的颇有前景的方式。
研究设计与样本
- 对照实验室研究。
- 体外:人肌腱细胞与人间充质干细胞分泌组(条件培养基)培养,并结合角蛋白静电纺丝支架。
- 体内:Wistar-Han大鼠(N=15)随机分为3组,每组n=5:未治疗病变组(MRCT组)、仅支架治疗组(scaffold-only组)、接种经hMSCs-CM预处理的人肌腱细胞的支架组(STC_hMSC_CM组)。
- 术后16周处死,取肩袖腱骨界面进行组织学分析和生物力学测试。
主要发现
- 体外:人间充质干细胞分泌组增加人肌腱细胞活力和密度。
- 组织学:STC_hMSC_CM组腱成熟评分(均值±标准误)15.6±1.08,显著高于MRCT组11.0±1.38(P<.05)。
- 生物力学:总断裂伸长率STC_hMSC_CM组11.99±3.30 mm、scaffold-only组9.89±3.47 mm、MRCT组5.86±3.16 mm,差异显著(P<.05)。
- 生物力学:刚度STC_hMSC_CM组6.25±1.74 N/mm、scaffold-only组6.72±1.28 N/mm、MRCT组11.54±2.99 N/mm,差异显著(P<.01)。
关键数值与推荐
- 腱成熟评分:STC_hMSC_CM组15.6±1.08 vs MRCT组11.0±1.38(P<.05)。
- 总断裂伸长率:STC_hMSC_CM组11.99±3.30 mm vs scaffold-only组9.89±3.47 mm vs MRCT组5.86±3.16 mm(P<.05)。
- 刚度:STC_hMSC_CM组6.25±1.74 N/mm vs scaffold-only组6.72±1.28 N/mm vs MRCT组11.54±2.99 N/mm(P<.01)。
临床怎么用
- 作者认为该工作支持进一步研究间充质干细胞分泌组预处理肌腱细胞。
- 作者认为该组织工程策略是颇有前景的方式,有助于改善慢性巨大肩袖撕裂的治疗结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Massive rotator cuff tears (MRCTs) represent a major clinical concern, especially when degeneration and chronicity are involved, which highly compromise healing capacity. PURPOSE: To study the effect of the secretome of mesenchymal stem cells (MSCs) on tendon cells (TCs) followed by the combination of these activated TCs with an electrospun keratin-based scaffold to develop a tissue engineering strategy to improve tendon-bone interface (TBi) healing in a chronic MRCT rat model. STUDY DESIGN: Controlled laboratory study. METHODS: Human TCs (hTCs) cultured with the human MSCs (hMSCs) secretome (as conditioned media [CM]) were combined with keratin electrospun scaffolds and further implanted in a chronic MRCT rat model. Wistar-Han rats (N = 15) were randomly assigned to 1 of 3 groups: untreated lesion (MRCT group, n = 5), lesion treated with a scaffold only (scaffold-only group, n = 5), and lesion treated with a scaffold seeded with hTCs preconditioned with hMSCs-CM (STC_hMSC_CM group, n = 5). After sacrifice, 16 weeks after surgery, the rotator cuff TBi was harvested for histological analysis and biomechanical testing. RESULTS: The hMSCs secretome increased hTCs viability and density in vitro. In vivo, a significant improvement of the tendon maturing score was observed in the STC_hMSC_CM group (mean ± standard error of the mean, 15.6 ± 1.08) compared with the MRCT group (11.0 ± 1.38; P < .05). Biomechanical tests revealed a significant increase in the total elongation to rupture (STC_hMSC_CM, 11.99 ± 3.30 mm; scaffold-only, 9.89 ± 3.47 mm; MRCT, 5.86 ± 3.16 mm; P < .05) as well as a lower stiffness (STC_hMSC_CM, 6.25 ± 1.74 N/mm; scaffold-only, 6.72 ± 1.28 N/mm; MRCT, 11.54 ± 2.99 N/mm; P < .01). CONCLUSION: The results demonstrated that hMSCs-CM increased hTCs viability and density in vitro. Clear benefits also were observed when these primed cells were integrated into a tissue engineering strategy with an electrospun keratin scaffold, as evidenced by improved histological and biomechanical properties for the STC_hMSC_CM group compared with the MRCT group. CLINICAL RELEVANCE: This work supports further investigation into the use of MSC secretome for priming TCs toward a more differentiated phenotype, and it promotes the tissue engineering strategy as a promising modality to help improve treatment outcomes for chronic MRCTs.
引用
- Sevivas N, Teixeira FG, Portugal R, et al. Mesenchymal Stem Cell Secretome Improves Tendon Cell Viability In Vitro and Tendon-Bone Healing In Vivo When a Tissue Engineering Strategy Is Used in a Rat Model of Chronic Massive Rotator Cuff Tear. Am J Sports Med. 2017. PMID: 29053925. doi:10.1177/0363546517735850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。